Adjuvant Therapy of Primary Breast Cancer VI pp 341-352
Anti-angiogenesis Therapy and Strategies for Integrating It with Adjuvant Therapy
The growth of tumors above about 1 mm in diameter requires angiogenesis, the development of a new blood supply, from pre-existing vasculature (Folkman 1990). This applies to both the primary and secondary lesions. Angiogenesis is also essential for systemic metastasis, and it has recently been shown that it is essential for local invasion (Skobe et al. 1997). Normal vasculature is quiescent and each endothelial cell divides only once in 10 years, apart from the endometrial and ovarian angiogenesis during the menstrual cycle and during wound healing. In human tumors the number of dividing endothelial cells may be 50 times greater than in normal tissue. These vessels are leaky, have upregulated vascular growth factor receptors and cell adhesion molecules and are in a procoagulant state. Thus they provide a new therapeutic target with many factors differently expressed between tumor and normal endothelium. This review describes some of the angiogenic pathways and discusses how emerging anti-angiogenic drugs can be integrated into adjuvant trials.
Unable to display preview. Download preview PDF.
- Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM (1995) Synergistic effect of vascular endothelial growth-factor and basic fibroblast growth-factor on angiogenesis in vivo. Circulation 92:365–371Google Scholar
- Chan HY, Harris AL (1996) Gene therapy targeting to tumor endothelium. In: Sobol RE, Scanlon KJ (eds) The internet book of gene therapy — cancer therapeutics. Appleton and Lange, Stamford, pp 211–227Google Scholar
- Clapp C, Delaescalera GM (1997) Prolactins — novel regulators of angiogenesis. News Physiol Sci 12:231–237Google Scholar
- Gasparini G, Harris AL (1997) p53 and angiogenesis in neoplasia. In: Klijn JGM (ed) Prognostic and predictive value of p53. Elsevier, Rotterdam, pp 115–130Google Scholar
- Petit AMV, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS (1997) Neutralizing antibodies against epidermal growth-factor and erbb-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo — angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530PubMedGoogle Scholar
- Relf M, Lejeune S, Scott PAE, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial-cell growth-factor, acidic and basic fibroblast growth-factor, tumor-growth factor-beta-1, platelet derived endothelial-cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963–969PubMedGoogle Scholar
- Vermeiden PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezella F, Viale G, Weidner N, Harris AL, Dirix LY (1996) Qunatification of angiogenesis in solid human tumors — an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474–2484Google Scholar
- Wamil BD, Thurman GB, Sundell HW, Devore RF, Wakefield G, Johnson DH, Wang YF, Helleqvist CG (1997) Soluble e-selection in cancer patients as a marker of the therapeutic efficacy of cm 101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol 123:173–179PubMedCrossRefGoogle Scholar
- Yue TL, Wang XK, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ (1997) 2-methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis — possible role for stress-activated protein-kinase signaling pathway and fas expression. Mol Pharmacol 51:951–962PubMedGoogle Scholar